We are pleased to invite you to an evening of education and networking exploring the evolving role of bispecific antibodies in multiple myeloma care. Hosted across multiple locations throughout Victoria and Tasmania, this event will feature expert presentations on the latest evidence, treatment considerations and practical nursing management. Kindly sponsored by J&J, GSK, Abbvie and BD.
This August we are bringing everyone together in VIC/TAS with an extraordinary event. With our main venue at Miss Mi in Melbourne (at the iconic Movenpick Hotel Melbourne), opposit Southern Cross Station, you are only one train ride away from attending! We are also hosting a flagship site in Hobart at Tesoro (at the unique Movenpick Hotel Hobart). Additional satellite sites will be located in Launceston, Ballarat, Bendigo and Warrnambool, for better coverage of the event throughout our two states.
Join us for an engaging and informative evening exploring the evolving role of bispecific antibodies in the treatment of multiple myeloma. As these innovative therapies become increasingly integrated into clinical practice, cancer nurses play a critical role in supporting patients throughout their treatment journey.
This educational dinner will provide attendees with valuable insights into the current landscape of bispecific antibody therapies in multiple myeloma care, including their mechanism of action, emerging evidence, and place within contemporary treatment pathways. Expert presenters will also discuss the unique nursing considerations associated with these therapies, equipping participants with practical strategies to optimise patient outcomes.


Clinical Haematologist Clinical Trials – Myeloma CAR-T Service B, Bayside Health - Alfred Care Group

Myeloma Nurse Practitioner
Daniela Klarica is a myeloma nurse practitioner at The Alfred Hospital. She has more than 20 years’ experience caring for haematology patients and was endorsed as a myeloma nurse practitioner in 2017. Daniela’s role is primarily based in the outpatient setting where she cares and supports patients and their families with myeloma in all aspects of their treatment phase from diagnosis through to end of life care including the supportive care of patients while receiving bi-specific antibodies. In 2015 Daniela successfully developed and implemented an innovative nurse-led community based bortezomib program, enabling patients more time at home. Daniela is a pivotal member of the Alfred myeloma team, attending the weekly plasma cell disorder clinic where she assesses and manages people with monoclonal gammopathy of undetermined significance.

Clinical Haematologist Clinical Trials – Myeloma CAR-T Service B, Bayside Health - Alfred Care Group
MBBS PhD FRACP FRCPA
Sueh-li Lim is a Clinical Haematologist and Clinician-Researcher with a special interest in multiple myeloma. Currently she serves as the Myeloma Clinical Trials Lead and the Myeloma Lead for the CAR-T cellular therapies service, Alfred Hospital and Myeloma Lead, Latrobe Regional Hospital.
Please accept {{cookieConsents}} cookies to view this content